Scientific article
Open access

Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia

ContributorsSullerot, Coralie; Bouiller, Kevinorcid; Laborde, Marie-Caroline; Gilis, Marine; Fèvre, Amélie; Hacquin, Arthur; Manckoundia, Patrick; Hoefler, Florence; Bermejo, Messaline; Mendes Aguiar Santos, Aline; De Roux Serratrice, Christineorcid; Prendki, Virginie; Sanchez, Stéphane; Putot, Alainorcid; ESGIE (European Society of Clinical Microbiology, European Society of Clinical Microbiological and Infectious Diseases, Study Group for Infections in the Elderly)
Published inGeroScience, vol. 44, no. 2, p. 573-583
Publication date2022-04
First online date2022-01-07

Platelet aggregation has been associated with COVID-19 pathogenesis. In older patients hospitalized for SARS-CoV-2 pneumonia, we aimed to investigate the association between aspirin use before admission and the risk of in-hospital all-cause mortality. We performed a retrospective international cohort study in five COVID-19 geriatric units in France and Switzerland. Among 1,357 consecutive hospitalized patients aged 75 or older and testing positive for SARS-CoV-2, we included 1,072 with radiologically confirmed pneumonia. To adjust for confounders, a propensity score for treatment was created, and stabilized inverse probability of treatment weighting (SIPTW) was applied. To assess the association between aspirin use and in-hospital 30-day mortality, SIPTW-adjusted Kaplan-Meier and Cox proportional hazards regression analyses were performed. Of the 1047 patients with SARS-CoV-2 pneumonia and median age 86 years, 301 (28.7%) were taking aspirin treatment before admission. One hundred forty-seven (34.3%) patients who had taken aspirin died in hospital within 1 month vs 118 patients (30.7%) without aspirin. After SIPTW, aspirin treatment was not significantly associated with lower mortality (adjusted hazard ratio: 1.10 [0.81-1.49], P = .52). Moreover, patients on aspirin had a longer hospital stay and were more frequently transferred to the intensive care unit. In a large multicenter cohort of older inpatients with SARS-CoV-2 pneumonia, aspirin use before admission did not appear to be associated with an improved prognosis.

  • Aged
  • Antiplatelet
  • Aspirin
  • COVID-19
  • Coronavirus
  • Mortality
  • Pneumonia
  • Aged, 80 and over
  • Aspirin / therapeutic use
  • Cohort Studies
  • Humans
  • Inpatients
  • Retrospective Studies
  • SARS-CoV-2
Citation (ISO format)
SULLEROT, Coralie et al. Premorbid aspirin use is not associated with lower mortality in older inpatients with SARS-CoV-2 pneumonia. In: GeroScience, 2022, vol. 44, n° 2, p. 573–583. doi: 10.1007/s11357-021-00499-8
Main files (1)
Article (Published version)
ISSN of the journal2509-2723

Technical informations

Creation02/07/2023 8:37:50 AM
First validation05/22/2023 12:16:44 PM
Update time05/22/2023 12:16:44 PM
Status update05/22/2023 12:16:44 PM
Last indexation08/31/2023 11:15:28 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack